These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 27306802)

  • 1. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
    Okuyama R
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors in Hodgkin's lymphoma.
    Jezeršek Novaković B
    Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W; Gilligan BM; Yuan J; Li T
    J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
    Buchbinder EI; Desai A
    Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.